FDA Action on Loperamide Misuse; Plus Phase 1 Trials for BAT2506 Biosimilar Begin
How to Improve Opioid Prescribing in an Outpatient Clinic
Measles Is Back. How Does This Affect Patients with Rheumatic Disease?
FDA Approves Risankizumab, Adds Stronger Warning to Sleep Medications
FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare
Safety Risk with Higher Dose Tofacitnib
FDA Update: Priority Review for Non-Opioid Treatment & New Warning for Fluoroquinolones
The Perils of Pain Meds Revisited
Phase 2 Results for Mavrilimumab Are In
- 1
- 2
- 3
- …
- 17
- Next Page »